Feb. 10, 2026 — Capsadyn®, a next-generation non-burning capsaicin cream developed by Chorda Pharma Inc., is now available on Amazon in addition to direct sales through Capsadyn.com. The expanded distribution provides consumers with a convenient new way to access maximum-strength capsaicin pain relief — without the burning sensation commonly associated with traditional capsaicin creams.
“Capsadyn is an innovative treatment for joint and muscle pain based on years of research in the lab,” says CEO Victor Iannello, ScD. “The Amazon launch allows us to reach more pain sufferers who want a safe alternative that is gentle on the skin.”
Since launching on Amazon, Capsadyn has quickly gained momentum and is currently ranked as the #1 New Release in Arthritis Pain Relief Medications, signaling strong consumer demand for a gentler approach to topical pain relief.
Capsaicin creams have long been recognized as effective options for temporary relief of minor arthritis, joint, and muscle pain. However, many users discontinue use due to the uncomfortable burning or skin irritation often caused by conventional formulations. Capsadyn was developed to overcome this long-standing limitation. Clinical testing showed that even at the maximum OTC capsaicin strength (0.25%), Capsadyn produced no statistically significant difference in burning sensation compared with a placebo cream containing no capsaicin.
Because Capsadyn is highly concentrated, a small amount is designed to deliver effective relief, with each jar providing approximately 50 applications depending on individual use. The fast-absorbing, non-greasy formula is easy to use without mess or medicinal odor.
“Capsadyn is an innovative treatment for joint and muscle pain based on years of research in the lab,” says CEO Victor Iannello, ScD. “The Amazon launch allows us to reach more pain sufferers who want a safe alternative that is gentle on the skin.”
Capsadyn maximum-strength capsaicin cream contains no steroids, NSAIDs, or anesthetics and is manufactured in the United States in accordance with FDA regulations for external analgesics.
Consumers can learn more or purchase directly at Capsadyn.com, or find Capsadyn on Amazon at https://www.amazon.com/dp/B0G2TCNTSV
March 15, 2024. Chorda Pharma today announced positive top-line results from a clinical trial for studying the skin burning characteristics of Capsadyn™ (0.25%), an over-the-counter topical analgesic formulated as a proprietary capsaicin-based cream with a concentration of 0.25%. Capsadyn™’s burning properties were statistically equal to the placebo cream (p = 0.32). On the other hand, Zostrix® (0.1%), an over-the-counter topical cream with a capsaicin concentration of 0.1%, had burning properties significantly higher than the placebo (p = 0.001).
Download full release.
November 2, 2023. Chorda Pharma has announced that it is now offering Capsadyn™ for sale as an over the counter (OTC) analgesic topical cream. Unlike other topical analgesics containing capsaicin, Capsadyn™ does not irritate or the burn the skin, which improves tolerability and patient adherence to physician recommendations. Capsadyn™ provides a superior alternative to corticosteroids as well as other OTC medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, which are not safe for long-term treatment of pain. Capsadyn™ contains no opioids and is non-addictive. Capsadyn™ is the first in Chorda’s pipeline of future drugs under development to address these priorities.
Download full release.
June 27, 2022. The Virginia Innovation Partnership Corporation (VIPC) has notified Chorda Pharma that it will receive a grant from the Commonwealth Commercialization Fund (CCF) for the Commercialization of a Non-Opioid Topical Analgesic. The $75,000 award will be used to help fund the testing, pilot manufacturing, and marketing of Capsadyn™, which offers relief for patients suffering from chronic pain. Download full release.
June 2, 2021. Chorda Pharma is partnering with Carilion Clinic to develop, test, and market non-opioid medications to treat chronic pain. Download full release.
May 4, 2021. Serial entrepreneur and innovator Victor Iannello, Sc.D., has joined Roanoke-based Chorda Pharma as its CEO. Download full release.